Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002392 · ClinicalTrials.gov registry record · NA
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
A NA study of HIV Infections, sponsored by Rockefeller University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00002392: Completed NA study of HIV Infections, sponsored by Rockefeller University.
NCT00002392 is a NA study of HIV Infections that has completed, run by Rockefeller University. The registered enrollment target is 12 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002392, a NA study of HIV Infections, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and parameters of specific, anti-HIV cellular immunity.
Conditions Studied
Interventions
- DRUG Thalidomide
Study Locations (1)
New York
- Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Phase | NA |
What the finished NCT00002392 record still lists
NCT00002392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide is the first listed.
NCT00002392 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00002392 about?
NCT00002392 is a clinical study titled "A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART". To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and parameters of specific, anti-HIV cellular immunity.
What is the current status of trial NCT00002392?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants.
What conditions does trial NCT00002392 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002392?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00002392?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002392 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002392's enrollment target sits among peer trials
12 519th of 542 higher than 18 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning